Overview

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of darbepoetin alfa administered at a subcutaneous (SC) dose of 0.45 mcg/kg three times weekly (TIW) in anemic patients with non-myeloid malignancies receiving multicycle chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa